Background: Several methods for the early detection of colorectal cancer to reduce its mortality rate have been reported. Here, we investigated the potential of a fecal micro RNA test for the early detection of colorectal cancer. Methods: Patients with colorectal cancer (n = 299) and healthy volunteers (n = 116) with no abnormalities detected by screening colonoscopy were enrolled in this case-control study. Micro RNA expression in the colonocytes of patients with colorectal cancer (n = 47) and in healthy volunteers (n = 35) were analyzed in the training set, and the micro RNA expression in the colonocytes of patients with colorectal cancer (n = 252) and healthy volunteers (n = 81) was validated in the validation set. Results: In the training study, significant differences in the relative expression level of miR-17-92 cluster, -106a, -135, and -146a were observed between patients with colorectal cancer and healthy volunteers (P , 0.01). The area under the receiver operating characteristic curve using miR-17, -18a, -19a, -19b, -20a, -92a, -106a, -135b, and -146a was more than 0.7. The overall sensitivity and specificity in the training study using these micro RNAs was 70.2% (33/47) and 74.3% (26/35), respectively. The overall sensitivity and specificity in the validation study was 67.5% (170/252) and 75.3% (61/81), respectively. Conclusion: We have developed a fecal micro RNA test for exfoliated colonocytes for colorectal cancer screening. Further comparative study of this test for colorectal cancer screening is needed.
Introduction
The early stage of colorectal cancer is curable by surgical resection, thus a suitable colorectal cancer screening test is necessary to reduce its mortality rate. The fecal occult blood test has been used widely as a screening test for colorectal cancer. [1] [2] [3] However, large-scale studies have shown that the sensitivity of the fecal occult blood test is not very high using total colonoscopy as a reference standard in all subjects. [4] [5] [6] [7] Therefore, several attempts for the early detection of colorectal cancer have been reported. In fecal DNA-based analysis, the stool DNA test 6 was recommended as a colorectal cancer screening method. 8 Further, we have reported several DNA-based methods for the detection of early-stage colorectal cancer using direct sequence analysis 9 and singlestrand conformation polymorphism analysis 10 in exfoliated colonocytes. However, the sensitivity and specificity of the stool DNA test were insufficient compared with that of the fecal occult blood test. 11 Another technical issue was that several mutation sites of adenomatous polyposis coli (APC), Kras, and p53 genes in colorectal cancer tissue were not always identical in those genes. 12 In addition, the DNA mutation analysis was complicated and expensive. This may make the use of fecal DNA analysis for colorectal cancer screening unrealistic.
Gene expression analysis based on real-time reverse transcription polymerase chain reaction (RT-PCR) has been shown to be relatively simple and cost-effective. Several attempts to detect colorectal cancer by RT-PCR in fecal samples have been reported. [13] [14] [15] In those reports, the expression analyses of COX2 and MMP7 in fecal RNA, and COX2, MMP7, MYBL2, and TP53 in colonocyte RNA were conducted. 13, 15, 16 MicroRNAs (miRNAs) are small (18-25 nucleotide) noncoding RNA molecules that regulate the activity of specific mRNA targets and play a major role in development of cancer. miRNA downregulates multiple target gene expressions by degrading mRNA or blocking its translation into protein through RNA interference. 17, 18 Several miRNAs, such as miRNA-21 (miR-21), the miR-17-92 cluster and miR-135, were found to be highly expressed in colorectal cancer tissue. [19] [20] [21] [22] Several recent studies have clarified that the circulating miRNA in plasma is a potential marker for detection of colorectal cancer, 23, 24 and is remarkably stable in plasma and protected from endogenous RNase activity. 25 We have developed a fecal miRNA test using colonocyte RNA. 26 In the present study, we analyzed several miRNAs using an optimal internal control to improve the accuracy of the fecal miRNA test. Following selection of a suitable target and threshold in the training study, the fecal miRNA test was evaluated in a validation study to determine its potential for early detection of colorectal cancer.
Materials and methods

Fecal samples and isolation of exfoliated cells
Naturally evacuated fecal samples were obtained from patients with colorectal cancer before surgical resection. Fecal samples were also obtained from healthy volunteers a few weeks after screening colonoscopy. All patients with colorectal cancer and healthy volunteers were instructed to evacuate at home into a disposable 5 × 10 cm polystyrene tray (AsOne, Osaka, Japan) and then bring the sample to the reception counter at the outpatient clinic or the Cancer Prevention and Screening Center of the National Cancer Center. The fecal samples were processed immediately after they were brought to our laboratory.
For the isolation of colonocytes from naturally evacuated feces, we used two kinds of immunomagnetic beads tagged with antihuman EpCAM monoclonal antibodies, ie, Dynabeads Epithelial Enrich (Dynal, Oslo, Norway) and JSR beads (JSR, Tsukuba, Japan). 27 The ability to isolate cells from feces using Dynal beads and JSR beads was almost same. The samples were processed as described previously. 9 Briefly, the fecal sample was homogenized with a buffer (40 mL) consisting of Hanks' solution, 10% fetal bovine serum, and 25 mM HEPES buffer (pH 7.35) at 200 rpm for one minute using a Stomacher system (Seward, Thetford, UK). The homogenate was filtered through a nylon filter (pore size, 512 µm), and following the addition of 80 µL of the immunomagnetic beads, the sample mixture was incubated for 30 minutes under gentle rolling conditions at room temperature. The mixture on the magnet was incubated on a shaking platform for 15 minutes at room temperature. The supernatant was then removed and the colonocytes in the pellet were stored at −80°C until RNA extraction.
miRNA array for selection of internal control and target miRNA
To determine the internal control for miRNA analysis and the suitable target of miRNA, the colonocyte RNA of five patients with colorectal cancer and five healthy volunteers was analyzed using the TaqMan MicroRNA Array v3.0 (Applied Biosystems, Foster, CA), in accordance with the manufacturer's instructions. RT-PCR was performed using an Applied Biosystems 7900HT fast real-time PCR system. Next, the target miRNAs were validated using total RNA extracted from both the cancer tissue and the normal mucosa of 31 patients with colorectal cancer. colonoscopy performed at the Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo. The median age of the healthy volunteers was relatively younger than that of the patients with colorectal cancer. Regarding gender, the number of women was relatively higher among the healthy volunteers than among the patients with colorectal cancer. All participants were provided with detailed information about the study, and each gave written informed consent to participate in the study, which was approved by the institutional review board of National Cancer Center, Japan.
miRNA expression analysis using real-time PCR
Total RNA was extracted from the colonocytes isolated from the fecal samples using an miRNeasy Mini Kit (QIAGEN, Valencia, CA), and cDNA was synthesized using a TaqMan MicroRNA RT Kit (Applied Biosystems), in accordance with the manufacturer's instructions. RT-PCR was performed with precycling heat activation at 95°C for 20 seconds, followed by 40 cycles of denaturation at 95°C for 3 seconds, and annealing/ extension at 60°C for 30 seconds, using an Applied Biosystems 7500 fast RT-PCR system. For the analysis of all miRNAs, we used the TaqMan microRNA assay (Applied Biosystems). miRNA expression analysis was conducted using the comparative Ct (threshold cycle) method. In this analysis, the formulae for the relative quantification of each gene were as follows: (dCt of each miRNA) = (Ct of each miRNA) − (Ct of miR-24), and (relative quantification of each miRNA) = 2 −(dCt of each miRNA)
.
Statistical analysis
Differences in relative quantification of the miRNAs were analyzed using the two-sided Mann-Whitney U-test. Statistical analyses were performed using SPSS Statistics version 19 for Windows (IBM, Tokyo, Japan). P , 0.05 was considered to indicate a statistically significant difference.
Results
Suitable internal control of miRNA analysis
Of 749 miRNAs, the average number of PCR-successful miRNA was 180 (range 90-295) in patients with colorectal cancer and 157 (53-242) in healthy volunteers, respectively. Forty miRNAs could be detected in all five patients with colorectal cancer and five healthy volunteers using the TaqMan MicroRNA Array, and these miRNAs served as candidates for internal control (Figure 1 
Selection of target miRNAs for colorectal cancer detection
According to the results of miRNA array, 20 miRNAs were selected as candidates for miRNA analysis ( Relative quantification of each miRNA in colonocytes
The relative expression level of each miRNA was calculated using that of miR-24 as an internal control for 47 patients with colorectal cancer and 35 healthy volunteers in the training set (Table 1) . We observed significant differences in the relative expression level of miR-17, -18a, -19a, -19b, -20a, -92a, -106a, -135a, -135b, and -146a between the patients with colorectal cancer and the healthy volunteers (P , 0.01). On the other hand, there was no significant difference in the relative expression level of miR-21, -183, -223, and -454* between the colorectal cancer patients and the healthy volunteers (P . 0.1, Table 3 ).
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Area under ROC curve
The data for sensitivity and specificity calculated using relative quantifications of miRNA in patients with colorectal cancer and healthy volunteers were blotted into a receiver operating characteristic (ROC) curve (Figure 2) . Areas under the ROC curve using miR-21, -135a, -183, -223, and -454* were less than 0.6. On the other hand, areas under the ROC curve using miR-17, -18a, -19a, -19b, -20a, -92a, -106a, -135b, and -146a were more than 0.7.
Sensitivity and specificity of miRNA expression analysis in training study
From the abovementioned results, we set miR-17, -18a, -19a, -19b, -20a, -92a, -106a, -135b, and -146a as a new miRNA set for detection of colorectal cancer. The thresholds of miR-17, -18a, -19a, -19b, -20a, -92a, -106a, -135b, and -146a were 2.1, 0. 16 
Sensitivity and specificity of miRNA expression analysis in validation study
After the training study, 252 patients with colorectal cancer and 81 healthy volunteers were validated in the validation study ( Table 1) . The thresholds of all miRNAs for the validation study were the same as those for the training study. The overall sensitivity of the patients with colorectal cancer and the specificity of the healthy volunteers were 67.5% (170/252, 95% CI 61.3-73.2) and 75.3% (61/81, 95% CI 64.5-84.2), respectively (Table 5 ). There was no remarkable difference between the training study and the validation study.
Discussion
In our recent preliminary study, we analyzed the expression of miRNA in exfoliated colonocytes using oncogenic miRNAs, such as the miR-17-92 cluster, miR-21, and miR-135 normalized by U6. 26 We found that the expression analysis on the miRNA extracted from exfoliated colonocytes was feasible. In the present study, we adopted a more suitable internal control for miRNA expression and the optimal miRNA set for detecting colorectal cancer using TaqMan MicroRNA Notes: P value was analyzed by the Mann-Whitney U-test and P , 0.05 was considered to indicate a statistically significant difference. Abbreviation: RQ, relative quantification. Array. The highly stable expression in both patients with colorectal cancer and in healthy volunteers was necessary for the internal control. Because expression of miR-24 in the colonocytes of patients with colorectal cancer and healthy volunteers was more stable and constant than that of the miR-200 family or U6 that are sometimes used as a provisional internal control, miR-24 was adopted as an internal control in the present study. However, miR-24 was not used as an internal control in previous studies. Therefore, we believe that establishment of a universal internal control for miRNA analysis is urgently needed. The miR-17-92 cluster, -21, -34a, -106a, -135, -146a, -155, -183, -191, -206, -223, -454*, -564, and -1208 were selected from 749 miRNAs as candidates for miRNA analysis using TaqMan MicroRNA Array. Among those, the miR-17-92 cluster, -21, -106a, -135, -146a, -183, -223, and -454* were highly expressed in colorectal cancer tissue compared with the normal mucosa in our preliminary results. To date, various reports have shown that the miR-17-92 cluster, -21, -106a, -135, and -223 were expressed more strongly in colorectal cancer tissue than in normal colorectal tissue. [19] [20] [21] [22] [28] [29] [30] [31] Though it has been shown that miR-146a is highly expressed in several types of cancer tissue, 32, 33 it has been reported that miR-146a is tumor suppressor miRNA. 34 These results are controversial; however, miR-146a was expressed to a significantly greater extent in colorectal cancer tissue than in normal mucosa in our study. Thus, we decided to use miR-17-92 cluster, -21, -106a, -135, -146a, -183, -223, and -454* for colorectal cancer detection using colonocytes in the present study.
In the training study, the expressions of miR-21, -183, -223, and -454* in exfoliated colonocytes of patients with colorectal cancer were not significantly different from those of healthy volunteers. Because relative expression of miR-135a was low in both patients with colorectal cancer and healthy volunteers, the area under the ROC curve using miR-135a was under 0.6. From the present results, we determined that miR-17, -18a, -19a, -19b, -20a, -92a, -106a, -135b, and -146a were useful for detection of colorectal cancer. The sensitivity and specificity of the miRNA assay in colonocytes was 70.2% and 74.3%, respectively. These results are almost the same as those of our previous studies, 9,10,16 and we have subsequently validated the miRNA set in the validation study.
Although the rate of patients with early-stage colorectal cancer was slightly high in the validation study compared with the training study, there were no remarkable changes between the characteristics of the training study and those of the validation study. The sensitivity and specificity of the miRNA assay in the validation study was 67.56% and 75.3%, respectively. The sensitivity and specificity of the fecal miRNA test were almost the same between the training study and the validation study. Furthermore, we could not find any specific difference between miRNA expression and the clinicopathological characteristics of colorectal cancer.
In summary, the fecal miRNA test using miR-17, -18a, -19a, -19b, -20a, -92a, -106a, -135b, and -146a was found to be useful for the detection of colorectal cancer in both the training study and the validation study. The present data may warrant further comparative study between fecal occult blood test and the fecal miRNA test for colorectal cancer screening in terms of sensitivity, specificity, and cost-effectiveness. 
